Testavec is the first gene therapy company in the UK that focuses on screening the safety of gene therapy vectors. Its innovative technology was developed in collaboration with UCL, KCL, GeneWerk, the National Institute for Biological Standards and Control and NMI. The project won the SBRI, InMutaGene CRACK-IT Challenge funded by GSK and Novartis via the NC3Rs. It introduced the first human induced pluripotent stem cell (iPSc) based platform that evaluates virus vector safety prior to clinical use and a pre-screen for patient tolerance of gene therapy for which patent applications have been filed. TestaVec Ltd is a spin-out of Brunel University to provide a comprehensive service that tests GT safety and efficacy intended for academic and pharmaceutical use in the clinic.